NCT07166263View on ClinicalTrials.gov

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Gastric Cancer (GC)Colorectal Cancer
Interventions
DRUG

NK510

NK510 will be administered through intravenous infusion, once a week for a total of six times.

DRUG

NK510

NK510 will be administered through intraperitoneal perfusion on D1, D4, and D7 of the first week for a total of 3 times, with each 3-week cycle constituting a total of 2 cycles.

Trial Locations (1)

Unknown

Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University, Nanjing

All Listed Sponsors
lead

Base Therapeutics (Shanghai) Co., Ltd.

INDUSTRY